Colospan Announces FDA Approval of IDE for Intraluminal Bypass Device – an Alternative approach to Diverting Stoma

Colospan which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption (IDE) application. With this IDE approval in hand, the company will launch its pivotal study for CG-100, a temporary Intraluminal Bypass Device, designed to reduce diverting stoma rates in patients undergoing gastrointestinal resection procedures.

AMIT Invests $0.5M in Colospan

Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that AMIT (The Alfred Mann Institute at the Technion) has invested $0.5M in the company.

Colospan Recruits $2M in its Second Funding Round

Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that it completed the 2nd round of funding, totaling $2M, from VI Ventures and the existing investors.